Stem Cell Treatment Claims: How to Check FDA Status and Trial Registration

By the Regenerative Evidence Guide Team

A Clinic Says Its Stem Cell Treatment Is “FDA-Registered.” Here’s What to Check Before You Believe That.

Imagine you’re researching a stem cell treatment for a knee, back, or neurological condition. The clinic’s website says the product is “FDA-registered” and links to a study on ClinicalTrials.gov. It sounds official. But according to the FDA, that combination of words is often used to mislead patients, not to prove a product is safe, effective, or legally approved. Before you schedule a consultation or make a payment, there’s a short, checkable process for finding out what a claim like this actually means.

Read This First: A Warning Directly From FDA

The FDA has stated plainly that many stem cell and other regenerative medicine products marketed today are unapproved. This includes products made from a patient’s own cells, such as stem cells, fat-derived (stromal vascular fraction) cells, umbilical cord blood or cord blood stem cells, amniotic fluid, Wharton’s jelly, ortho-biologics, and exosomes.

The agency has specifically warned that some clinics point patients to ClinicalTrials.gov, or say a product is “FDA-registered,” to suggest the product is legally compliant. FDA states this is often false: being listed in the ClinicalTrials.gov database, or a company registering with FDA and listing its product, does not mean the product is legally marketed or has been reviewed for safety or effectiveness.

FDA has also stated that if you are being charged for one of these products, or offered one, outside of a clinical trial that FDA oversees, you are likely being offered a product illegally marketed to you.

Stage One: Separate “Registered” From “Approved”

These two words are not interchangeable, and the difference matters:

• FDA-approved or FDA-licensed means the specific product has gone through FDA’s formal review process for that intended use.
• Registered with FDA can simply mean a manufacturer has listed itself and its product with the agency, a step that does not require FDA to have evaluated whether the product works or is safe.
• Listed on ClinicalTrials.gov means a study involving the product has been registered in the database. It does not mean the study has finished, that FDA is overseeing it, or that the product is approved for the condition being marketed to you.

According to the FDA, the only stem cell products approved for use in the United States are blood-forming stem cells (hematopoietic progenitor cells) derived from umbilical cord blood, and they are approved only for disorders affecting blood production—not for orthopedic, neurological, cosmetic, or general anti-aging use.

Stage Two: Check the Trial Listing Yourself

If a clinic names a specific study or NCT number, you can view the record directly on ClinicalTrials.gov rather than taking their summary at face value. A study record is organized into a few sections worth checking:

• Descriptive and recruitment information — what the study is testing, who can enroll, and its current recruitment status.
• Results tab — this will say one of three things: “No Study Results Posted,” “Results Submitted” (submitted but not yet public), or it will show posted results covering participant flow, baseline characteristics, outcome measures, and adverse events.
• Administrative information — who sponsors the study and who is listed as the responsible party.

A practical rule: if a clinic references a trial but the record shows no posted results, that trial cannot yet tell you whether the treatment works or is safe. A registered trial is a starting point for research, not proof of an outcome.

Stage Three: Watch for These Specific Red Flags

FDA has identified specific marketing claims that should raise concern. As of FDA’s most recent public notice, regenerative medicine therapies have not been approved to treat COVID-19 or its complications; autism; macular degeneration or blindness; chronic pain or fatigue; multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, epilepsy, or stroke; heart disease, emphysema, or COPD; or orthopedic conditions such as osteoarthritis, tendonitis, disc disease, or joint and back pain.

If a clinic markets a stem cell or exosome product for any of these uses outside an FDA-overseen clinical trial, that is a claim to question directly, not a reason to proceed on trust.

Stage Four: Understand the Real Safety Risks

FDA has received reports connecting unapproved regenerative medicine products to serious harm, including blindness, tumor formation, neurological events, and bacterial infections, including life-threatening blood infections. Other documented risks include reactions at the collection or injection site, unwanted immune or inflammatory responses, cells migrating to unintended locations in the body, and cross-contamination with bacteria, viruses, or mold during processing.

This information is provided so you can ask informed questions — it is not a reason to avoid legitimate, FDA-overseen research, and it is not a substitute for a conversation with your own physician about your specific situation.

A Simple Decision Path Before You Move Forward

• Ask for the exact regulatory status in writing. “Approved,” “cleared,” “registered,” and “listed” mean different things — ask the clinic to specify which one applies and for what condition.
• Look up any cited trial yourself on ClinicalTrials.gov and check the Results tab before accepting a claim about outcomes.
• Confirm whether treatment is happening inside or outside an FDA-overseen trial. If you are being charged for the product outside such a trial, FDA has said this signals illegal marketing.
• If you’re unsure, contact FDA directly at ocod@fda.hhs.gov with your questions before proceeding.
• If you’ve already been treated and had a bad reaction, FDA encourages you to report it through the MedWatch Adverse Event Reporting program.

If you are experiencing a medical emergency, contact your local emergency services immediately rather than researching this checklist.

What This Article Is — and Isn’t

This guide is meant to help you evaluate marketing claims and registration status before a decision, not to diagnose a condition, recommend a treatment, or tell you whether a specific product is right for you. Those are questions for a licensed physician familiar with your medical history.

Regenerative Evidence Guide is an independent educational publication and is not affiliated with any clinic, training academy, faculty, conference, or treatment provider. We do not sell, endorse, or refer patients to any regenerative medicine product or provider.

For more on how we evaluate and source claims like these, see our How We Research page. If you’re new to this topic, our Start Here page is a good next stop.

This article is for general educational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare provider. Last updated: September 2026.

By Regenerative Evidence Guide Editorial Team